case_images: PMC11184230_01
case_images: Timeline of events.
case_images: OTT-17-489-g0001.jpg
case_images: PMC11184230_01_OTT-17-489-g0001.jpg
case_images: f0001
case_images: A summary of the events is presented in Figure 1.
case_images: Serial computed tomography imaging of the chest. The images portray the target right upper lobe (RUL) and right lower lobe (RLL) lesions at baseline (progression on previous ATP-competitive FGFR inhibitor, prior to starting futibatinib) at the first response evaluation time point (3 months after commencing futibatinib), at the time of maximum tumour shrinkage (12 months after commencing futibatinib), and at the present time (20 months after commencing futibatinib).
case_images: OTT-17-489-g0002.jpg
case_images: PMC11184230_01_OTT-17-489-g0002.jpg
case_images: f0002
case_images: Prior to commencing futibatinib, the dominant right base mass measured 11x10 cm (Figure 2).